The only therapy for a patient with end-stage liver disease (ESLD) is liver transplantation, which is performed by using either a cadaveric liver from a deceased donor or a portion of a living-donor's liver. This study addresses the following decision problem for an ESLD patient with an...

Cadaveric liver transplantation is the only viable therapy for end-stage liver disease patients without a living donor. However, this type of transplantation is hindered in the United States by donor scarcity and rapid viability decay. Given these difficulties, the current U.S. liver allocation...

Living donors are a significant and increasing source of livers for transplantation, mainly because of the insufficient supply of cadaveric organs. We consider the problem of optimally timing a living-donor liver transplant to maximize the patient's total reward, such as quality-adjusted life...